Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.1
(-0.5%)
SEK 0.1
(-0.5%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.09 Million SEK | -51.66% |
| 2022 | 2.25 Million SEK | -32.59% |
| 2021 | 3.34 Million SEK | -62.02% |
| 2020 | 8.81 Million SEK | -18.83% |
| 2019 | 10.86 Million SEK | 9.09% |
| 2018 | 9.95 Million SEK | 34.66% |
| 2017 | 7.39 Million SEK | 221.75% |
| 2016 | 2.29 Million SEK | 5.5% |
| 2015 | 2.17 Million SEK | 77.07% |
| 2014 | 1.23 Million SEK | 651.21% |
| 2013 | 163.73 Thousand SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 704 Thousand SEK | -35.82% |
| 2024 Q1 | 1.09 Million SEK | 0.55% |
| 2023 Q4 | 1.09 Million SEK | -60.26% |
| 2023 Q3 | 2.74 Million SEK | 48.3% |
| 2023 Q1 | 2.22 Million SEK | -1.37% |
| 2023 Q2 | 1.85 Million SEK | -16.85% |
| 2023 FY | 1.09 Million SEK | -51.66% |
| 2022 FY | 2.25 Million SEK | -32.59% |
| 2022 Q4 | 2.25 Million SEK | -26.31% |
| 2022 Q3 | 3.06 Million SEK | 256.99% |
| 2022 Q2 | 858 Thousand SEK | -6.13% |
| 2022 Q1 | 914 Thousand SEK | -72.7% |
| 2021 Q2 | 8.8 Million SEK | -0.65% |
| 2021 Q3 | 5.83 Million SEK | -33.72% |
| 2021 FY | 3.34 Million SEK | -62.02% |
| 2021 Q1 | 8.86 Million SEK | 0.58% |
| 2021 Q4 | 3.34 Million SEK | -42.66% |
| 2020 Q3 | 8.98 Million SEK | -7.63% |
| 2020 Q2 | 9.73 Million SEK | -10.49% |
| 2020 FY | 8.81 Million SEK | -18.83% |
| 2020 Q4 | 8.81 Million SEK | -1.92% |
| 2020 Q1 | 10.87 Million SEK | 0.09% |
| 2019 Q3 | 10.23 Million SEK | 12.11% |
| 2019 FY | 10.86 Million SEK | 9.09% |
| 2019 Q4 | 10.86 Million SEK | 6.09% |
| 2019 Q2 | 9.13 Million SEK | -12.74% |
| 2019 Q1 | 10.46 Million SEK | 5.11% |
| 2018 Q4 | 9.95 Million SEK | 11.8% |
| 2018 FY | 9.95 Million SEK | 34.66% |
| 2018 Q1 | 7.66 Million SEK | 3.72% |
| 2018 Q2 | 8.33 Million SEK | 8.69% |
| 2018 Q3 | 8.9 Million SEK | 6.85% |
| 2017 Q4 | 7.39 Million SEK | 20.65% |
| 2017 FY | 7.39 Million SEK | 221.75% |
| 2017 Q1 | 3.34 Million SEK | 45.61% |
| 2017 Q2 | 4.61 Million SEK | 38.02% |
| 2017 Q3 | 6.12 Million SEK | 32.7% |
| 2016 Q2 | 1.74 Million SEK | 6.03% |
| 2016 FY | 2.29 Million SEK | 5.5% |
| 2016 Q1 | 1.64 Million SEK | -24.56% |
| 2016 Q4 | 2.29 Million SEK | -18.78% |
| 2016 Q3 | 2.82 Million SEK | 62.4% |
| 2015 Q4 | 2.17 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | 2.17 Million SEK | 77.07% |
| 2014 FY | 1.23 Million SEK | 651.21% |
| 2013 FY | 163.73 Thousand SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alzinova AB (publ) | -3.27 Million SEK | 133.282% |
| Amniotics AB (publ) | 534 Thousand SEK | -104.307% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 94.659% |
| Genovis AB (publ.) | 14.9 Million SEK | 92.68% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 96.903% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 226.42% |
| Saniona AB (publ) | 1.00 SEK | -109099900.0% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | 2.08 Million SEK | 47.548% |
| Active Biotech AB (publ) | -2500.00 SEK | 43740.0% |
| Camurus AB (publ) | 100.95 Million SEK | 98.919% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 72.955% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 73518.573% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 56048.718% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 167.097% |
| NextCell Pharma AB | 545.23 Thousand SEK | -100.096% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 98.979% |
| Xintela AB (publ) | 398 Thousand SEK | -174.121% |
| Ziccum AB (publ) | -4.18 Million SEK | 126.044% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 344.079% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 97.508% |
| CombiGene AB (publ) | -1.79 Million SEK | 160.645% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 95.464% |
| Intervacc AB (publ) | 10.48 Million SEK | 89.593% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -54549900.0% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 115.289% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 128.286% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -109000.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 87.969% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 65.365% |
| Biovica International AB (publ) | 2.19 Million SEK | 50.387% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -109099900.0% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -55.857% |
| 2cureX AB (publ) | -1000.00 SEK | 109200.0% |
| I-Tech AB | 4.28 Million SEK | 74.509% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 88.858% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 122.134% |
| Nanologica AB (publ) | 2.97 Million SEK | 63.303% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 90.789% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 439.722% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 55.01% |
| Pila Pharma AB (publ) | 1.00 SEK | -109099900.0% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -6.128% |